Tinea Unguium disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: TNN002 MIFTS: 39	Tinea Unguium Categories: Infectious diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Tinea Unguium

MalaCards integrated aliases for Tinea Unguium:

Name: Tinea Unguium ¹² ¹⁵ ⁷² ³³

Cellulitis and Abscess of Upper Arm and Forearm ¹²

Cellulitis and Abscess of Finger and Toe ¹²

Cellulitis and Abscess of Gluteal Region ¹²

Cellulitis and Abscess of Buttock ¹²

Onychomycosis Due to Dermatophyte ¹²

Cellulitis and Abscess of Finger ¹²

Cellulitis and Abscess of Trunk ¹²

Cellulitis and Abscess of Face ¹²

Dermatophytic Onychomycosis ¹²

Dermatophytosis of Nail ¹²

Cellulitis and Abscess ¹²

Dermatophytic Onychia ¹²

Onychomycosis ⁷²

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Skin diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Certain infectious and parasitic diseases

Mycoses

Dermatophytosis

Tinea unguium

External Ids:

Disease Ontology ¹² DOID:13074

ICD9CM ³⁵ 681.9

ICD10 ³³ B35.1

UMLS ⁷² C0007644 C0040261 C4048550

Sources

Summaries for Tinea Unguium

Disease Ontology : ¹² A dermatophytosis that results in fungal infection located in nail, has material basis in Ascomycota fungi that belong to a group called dermatophytes, which cause separation of the nail plate from the nail bed and has symptom thickening of subungueal area. Sometimes, white islands are seen on the external nail plates. These gradually coalesce until the entire nail plate is involved.

MalaCards based summary : Tinea Unguium, also known as cellulitis and abscess of upper arm and forearm, is related to tinea pedis and tinea corporis, and has symptoms including thickening of subungueal area An important gene associated with Tinea Unguium is STAT1 (Signal Transducer And Activator Of Transcription 1), and among its related pathways/superpathways is Hfe effect on hepcidin production. The drugs Tazarotene and Nicotinamide have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and nail, and related phenotypes are growth/size/body region and mortality/aging

Wikipedia : ⁷⁵ Onychomycosis, also known as tinea unguium, is a fungal infection of the nail. Symptoms may include... more...

Sources

Related Diseases for Tinea Unguium

Diseases related to Tinea Unguium via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 55)

#	Related Disease	Score	Top Affiliating Genes
1	tinea pedis	32.0	SQLE ARSI
2	tinea corporis	31.1	SQLE ARSI
3	dermatophytosis	11.2
4	uvulitis	10.5
5	cellulitis	10.4
6	tinea cruris	10.4	SQLE PPIG
7	dermatomycosis	10.4
8	tinea capitis	10.4
9	leprosy 3	10.2
10	nail disorder, nonsyndromic congenital, 10	10.2
11	erythema multiforme	10.2
12	allergic hypersensitivity disease	10.2
13	paronychia	10.2
14	urticaria	10.2
15	keratosis	10.2
16	neuritis	10.2
17	human immunodeficiency virus infectious disease	10.2
18	bullous pemphigoid	10.2
19	chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids	10.2
20	hansen's disease	10.2
21	orbital cellulitis	10.2
22	immunodeficiency 17	10.2	STAT1 DDX41
23	tonsillitis	10.1
24	diarrhea	10.1
25	nail disease	10.1
26	48,xyyy	10.1
27	fish allergy	10.1	PPIG DDX41
28	dacryoadenitis	10.1
29	dacryocystitis	10.1
30	hemochromatosis, type 1	10.0	TMPRSS6 HLA-B HFE
31	retinitis pigmentosa, y-linked	9.9	PRDM10 POLB
32	retinal detachment	9.8
33	strabismus	9.8
34	kearns-sayre syndrome	9.8
35	yemenite deaf-blind hypopigmentation syndrome	9.8
36	crohn's colitis	9.8
37	sialadenitis	9.8
38	corneal edema	9.8
39	acute dacryocystitis	9.8
40	branch retinal artery occlusion	9.8
41	central retinal artery occlusion	9.8
42	uveitis	9.8
43	hidradenitis suppurativa	9.8
44	hidradenitis	9.8
45	retinal artery occlusion	9.8
46	impetigo	9.8
47	crohn's disease	9.8
48	chorioretinitis	9.8
49	mechanical strabismus	9.8
50	fasciitis	9.8

Graphical network of the top 20 diseases related to Tinea Unguium:

Sources

Symptoms & Phenotypes for Tinea Unguium

Symptoms:

¹²

• thickening of subungueal area

MGI Mouse Phenotypes related to Tinea Unguium:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	growth/size/body region	MP:0005378	9.7	ACOT11 CBSL CNBP HFE OPRM1 POLB
2	mortality/aging	MP:0010768	9.4	CBSL CNBP DDX41 HFE OPRM1 POLB

Sources

Drugs & Therapeutics for Tinea Unguium

Drugs for Tinea Unguium (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 67)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Tazarotene

Approved, Investigational

Phase 4

118292-40-3

5381

Nicotinamide

Approved, Investigational

Phase 4

98-92-0

936

Ciclopirox

Approved, Investigational

Phase 4

29342-05-0

2749

Amorolfine

Approved, Investigational

Phase 4

78613-35-1

Tavaborole

Approved, Investigational

Phase 4

174671-46-6

carbamide peroxide

Approved

Phase 4

124-43-6

Bifonazole

Approved, Investigational

Phase 4

60628-96-8

2378

Amphotericin B

Approved, Investigational

Phase 4

1397-89-3

14956 5280965

Dimethyl sulfoxide

Approved, Vet_approved

Phase 4

67-68-5

679

Efinaconazole

Approved

Phase 4

164650-44-6

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 4

59-30-3

6037

Niacin

Approved, Investigational, Nutraceutical

Phase 4

59-67-6

938

Keratolytic Agents

Phase 4

Trace Elements

Phase 4

Micronutrients

Phase 4

Vitamins

Phase 4

Folate

Phase 4

Vitamin B9

Phase 4

Nutrients

Phase 4

Vitamin B3

Phase 4

Vitamin B Complex

Phase 4

Nicotinic Acids

Phase 4

Pharmaceutical Solutions

Phase 4

Cytochrome P-450 CYP2C9 Inhibitors

Phase 4

Anti-Bacterial Agents

Phase 4

Antiparasitic Agents

Phase 4

Antiprotozoal Agents

Phase 4

Free Radical Scavengers

Phase 4

Liposomal amphotericin B

Phase 4

Antioxidants

Phase 4

Protective Agents

Phase 4

Luliconazole

Approved

Phase 2, Phase 3

187164-19-8

Fluconazole

Approved, Investigational

Phase 3

86386-73-4

3365

Cytochrome P-450 CYP2C19 Inhibitors

Phase 3

Econazole

Approved

Phase 2

27220-47-9

3198

Naftifine

Approved

Phase 2

65472-88-0

73342 47641

Aminolevulinic acid

Approved

Phase 2

106-60-5

137

Posaconazole

Approved, Investigational, Vet_approved

Phase 2

171228-49-2

147912

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Itraconazole

Approved, Investigational

Phase 2

84625-61-6

55283

Isotretinoin

Approved

Phase 2

4759-48-2

5282379 5538

Albaconazole

Investigational

Phase 2

187949-02-6

Immunologic Factors

Phase 2

Immunosuppressive Agents

Phase 2

Benzonidazole

Phase 2

Antifungal Agents

Phase 2

Anti-Infective Agents

Phase 2

14-alpha Demethylase Inhibitors

Phase 2

Hormones

Phase 2

Cytochrome P-450 CYP3A Inhibitors

Phase 2

Interventional clinical trials:

(show top 50) (show all 123)

#	Name	Status	NCT ID	Phase	Drugs
1	A Multicentre, Randomized, Controlled Study of the Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer Alone for the Treatment of Dermatophytic Onychomycosis (Toenail) Without Matrix Involvement	Unknown status	NCT01014637	Phase 4	Amorolfine (Antifungal);RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)
2	Evaluation of the Efficacy of CURE-EX Treatment in Onychomycosis	Unknown status	NCT02436291	Phase 4
3	Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study.	Unknown status	NCT03263624	Phase 4	Tazarotene Cream 0.1%
4	A Prospective, Double-blind, Placebo-controlled Trial of Topical Penlac Nail Lacquer for Therapy of Onychomycosis in Children	Completed	NCT01419847	Phase 4	Ciclopirox;Placebo
5	Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish	Completed	NCT03110029	Phase 4	Efinaconazole 10% Topical Application Solution [JUBLIA]
6	A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment	Completed	NCT02464826	Phase 4	Nailprotex
7	Efficacy of Topical Resin Lacquer, Amorolfine, and Oral Terbinafine for Treating Toenail Onychomycosis: a Prospective, Randomized, Controlled, Investigator-blinded, Parallel-group Clinical Trial	Completed	NCT01851590	Phase 4	Amorolfine;Terbinafine
8	Change in SCIO (Scoring Clinical Index For Onychomycosis) in Toenail Onychomycosis Treating With Itraconazole Capsules	Completed	NCT00871728	Phase 4	Itraconazole
9	An Investigator Initiated Pilot Study Evaluating the Efficacy of Efinaconazole 10% Solution (Jublia) for the Treatment of Onychomycosis With Dermatophytomas	Completed	NCT03098615	Phase 4	Jublia (Efinaconazole 10% Topical Solution)
10	Subject Adherence and Satisfaction for Treatment of Onychomycosis With Loceryl Nail Lacquer 5% Versus Ciclopirox Nail Lacquer	Completed	NCT02679911	Phase 4	Loceryl NL;Ciclopirox NL
11	Determination of Antifungal Activity of Loceryl Nail Lacquer 5% When Used Concomitantly With a Cosmetic Nail Varnish Compared to a Loceryl Nail Lacquer (NL) 5% Alone in Treatment of Toenail Distal Subungual Onychomycosis	Completed	NCT02321098	Phase 4	Loceryl NL + Cosmetic varnish;Loceryl NL 12 weeks;Loceryl NL 15 months
12	Subject Adherence and Satisfaction for Treatment of Onychomycosis With Loceryl Nail Lacquer 5% Versus a Fungal Nail Treatment Set Containing Urea 40% Ointment and Bifonazole Cream 1%	Completed	NCT02705664	Phase 4	Loceryl Nail Lacquer;Urea Ointment;Bifonazole Cream
13	An Open-label Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Kerydin (Registered) (Tavaborole) Topical Solution, 5% In The Treatment Of Onychomycosis Of The Toenail In Pediatric Subjects Ages 6 To 16 Years And 11 Months	Completed	NCT03405818	Phase 4	Tavaborole 5% Topical Solution
14	Comparison of the Efficacy and Safety Between Long-pulsed Nd:YAG, Amorolfine and Combination of Long-pulsed Nd:YAG and Amorolfine in Treating Non-dermatophyte and Mixed-infection Onychomycosis	Recruiting	NCT02812043	Phase 4	Amorolfine
15	Comparison of Effectiveness of Topical Amphotericin B in 30% Dimethylsulphoxide and 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis: Randomized Double Blind Controlled Trial Pilot Study	Recruiting	NCT03814343	Phase 4	amphotericin B in 30% DMSO;30% DMSO
16	A Multicenter, Open-label, Non-controlled, Single-arm Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis	Active, not recruiting	NCT03280927	Phase 4	Jublia®
17	A Multicenter, Open Label, Single-arm Study Evaluating the Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis of the Toenails	Active, not recruiting	NCT02812771	Phase 4	Efinaconazole
18	Treating Onychomychosis	Unknown status	NCT00776464	Phase 2, Phase 3
19	Study Efficacy and Safety in Comparative Use of Investigational Product Adjuvant Treatment in Onychomycosis	Unknown status	NCT02961634	Phase 3	Ciclopirox 8%
20	A Randomized, Double-blind, Vehicle- and Placebo-Controlled, Multicenter Trial in Patients With Mild to Moderate Distal Subungual Toenail Onychomycosis to Investigate the Efficacy, Tolerability, and Safety of Twice Daily Application of TDT 067 for 48 Weeks	Unknown status	NCT01145807	Phase 3	TDT067;Placebo;Transfersome
21	A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults	Completed	NCT01270971	Phase 3	AN2690 Topical Solution, 5%;Solution Vehicle
22	A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults	Completed	NCT01302119	Phase 3	AN2690 Topical Solution, 5%;Solution Vehicle
23	A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Topical Terbinafine Hydrogen Chloride (HCl) Formulation for 24 or 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis	Completed	NCT00443898	Phase 3	terbinafine;Placebo;terbinafine;Placebo
24	A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Topical Terbinafine Hydrogen Chloride (HCl) Formulation for 24 or 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis	Completed	NCT00443820	Phase 3	terbinafine;Placebo;terbinafine;Placebo
25	A Randomized, Open-label, Active-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride (HCl) Formulation Versus 5% Amorolfine Nail Lacquer for 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis	Completed	NCT00459537	Phase 3	terbinafine hydrogen chloride;amorolfine nail lacquer
26	A Multicenter, Randomized, Double-blind, Parallel, Vehicle-controlled Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Onychomycosis	Completed	NCT02549001	Phase 3	P-3058 10%;vehicle of P-3058 10%;amorolfine 5%
27	Multicentre, Open Label Study to Assess the Tolerability of P-3058 Nail Solution in Paediatric Patients Affected by Mild-to-moderate Onychomycosis	Completed	NCT02547701	Phase 3	P-3058
28	Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis	Completed	NCT01008033	Phase 3	IDP-108;Vehicle
29	The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis	Completed	NCT01007708	Phase 3	IDP-108;Vehicle
30	Safety and Efficacy of Luliconazole Solution, 10% With Two Dosing Regimens in Distal Subungual Onychomycosis of the Toenails: A Randomized, Double-Blind, Vehicle-Controlled, Phase 2B/3 Study	Completed	NCT01431820	Phase 2, Phase 3	Luliconazole Solution, 10%;Vehicle Solution
31	A Phase III Randomized, Evaluator-Blind, Parallel Group Study of the Safety and Efficacy of Itraconazole Tablets, Itraconazole Capsules and Placebo in the Treatment of Onychomycosis of the Toenail.	Completed	NCT00356915	Phase 3	Itraconazole 100mg capsules;Itraconazole 200mg tablets;Placebo tablets
32	A Double-blind, Randomized, Multicenter, Placebo- Controlled Phase 3 Trial to Prove the Superiority of Bifonazole vs. Placebo After 4 Weeks of Onychomycosis Treatment/ as a Follow-up of a 2 Weeks Treatment of Non-surgical Nail Ablation of Diseased Nail Matrix With 40% Urea Paste	Completed	NCT00781820	Phase 3	Bifonazole cream 1%;Placebo cream
33	Multi-Center Trial: Evaluation of PinPointe FootLaser Treatment for Infected Toenails (Onychomycosis)	Completed	NCT00935649	Phase 2, Phase 3
34	A Multi-centre, Randomized, Two-armed, Parallel Group and Evaluator-blinded Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)	Active, not recruiting	NCT02866032	Phase 3	MOB015B;Ciclopirox 80 mg/g
35	A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)	Active, not recruiting	NCT02859519	Phase 3	MOB015B;MOB015B Vehicle
36	Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients	Active, not recruiting	NCT03168841	Phase 3	Efinaconazole Topical
37	Comparative Study of Systemic Antifungal Drugs Used in Treatment of Onychomycosis	Not yet recruiting	NCT03171584	Phase 3	Terbinafine
38	A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenails for 52 Wks	Terminated	NCT01208168	Phase 3	NAB001;Vehicle alone
39	A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenails for 52 Weeks	Terminated	NCT01208129	Phase 3	NAB001;Placebo control
40	A Multicenter, Randomized, Double-blind, Parallel, Vehicle-controlled Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Onychomycosis	Withdrawn	NCT03094468	Phase 3	P-3058 (terbinafine hydrochloride 10%);Vehicle of P-3058
41	The Efficacy of CELEXT07 in the Treatment of Toenail Onychomycosis: a Phase 2, Randomized, Double-blind Study	Unknown status	NCT02644551	Phase 2	CELEXT07;Penlac
42	Noveon Laser Treatment of Onychomycosis: A Device Performance Clinical Study	Unknown status	NCT00771732	Phase 2
43	A Phase II Trial of the Safety, Local Tolerability, and Efficacy of EcoNail™ (Econazole 5%/SEPA® 18% Nail Lacquer) in Onychomycosis of the Great Toenail	Unknown status	NCT00385502	Phase 2	EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)
44	AVALIAÇÃO DO USO DO LASER ERBIUM-DOPED YTTRIUM ALUMINIUM GARNET (Er:YAG) ASSOCIADO AO ESMALTE DE AMOROLFINA NO TRATAMENTO DA ONICOMICOSE	Unknown status	NCT01528813	Phase 2	Amorolfine lacquer
45	Phase 2 Randomized, Multicenter, Placebo-controlled, Safety and Efficacy Study to Evaluate Three Oral E1224 Dosing Regimens and Benznidazole for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease	Unknown status	NCT01489228	Phase 2	E1224;Benznidazole;Placebo
46	Phase IIB Efficacy and Safety Study of Four Topical Gel Formulations of Anti-Fungal Agents, MQX-5858, MQX-5859, MQX-5866, and MQX-5867, Versus Vehicle in the Treatment of Tinea Unguium.	Completed	NCT00253305	Phase 2	Organogel of naftifine, 2%;Organogel of terbinafine, 2%;Organogel of naftifine, 6%;Organogel of terbinafine, 6%
47	An Unblinded Clinical Trial to Evaluate the Deposition of Terbinafine in the Nail Bed After Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail	Completed	NCT01484145	Phase 2	Terbinafine HCl
48	An Open-label, Multiple-dose Study Of The Absorption And Systemic Pharmacokinetics Of An2690 Applied As A 7.5% Solution To All Toenails Of Adult Patients With Moderate To Severe Onychomycosis	Completed	NCT00680160	Phase 2	AN2690
49	A Subject Blinded, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail	Completed	NCT01080079	Phase 2	Terbinafine Hydrochloride
50	A Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo-Controlled Study of the Safety & Efficacy of HTU-520 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail	Completed	NCT01400594	Phase 2	HTU-520 Patch

Search NIH Clinical Center for Tinea Unguium

Inferred drug relations via UMLS ⁷² / NDF-RT ⁵¹ :

ciclopirox

Ciclopirox olamine

Efinaconazole

Griseofulvin

Itraconazole

tavaborole

Tavaborole

terbinafine

Terbinafine

Terbinafine hydrochloride

Sources

Genetic Tests for Tinea Unguium

Sources

Anatomical Context for Tinea Unguium

MalaCards organs/tissues related to Tinea Unguium:

⁴¹

Testes, Skin

The Foundational Model of Anatomy Ontology organs/tissues related to Tinea Unguium:

¹⁹

Nail

Sources

Publications for Tinea Unguium

Articles related to Tinea Unguium:

(show top 50) (show all 269)

#	Title	Authors	PMID	Year
1	Internal environment of footwear is a risk factor for tinea pedis. ³⁸	Sasagawa Y	31436337	2019
2	Tinea unguium caused by terbinafine-resistant Trichophyton rubrum successfully treated with fosravuconazole. ³⁸	Noguchi H...Ihn H	31353607	2019
3	Epidemiology of dermatophytosis in northeastern Iran; A subtropical region. ³⁸	Ebrahimi M...Novak Babic M	31321333	2019
4	Epidemiology of dermatophytic infections between 2008 and 2017 in Barcelona, Spain. ³⁸	Antuori A...Matas L	31076176	2019
5	Terbinafine-resistant strain of Trichophyton interdigitale strain isolated from a tinea pedis patient. ³⁸	Hiruma J...Harada K	30768808	2019
6	Differences Between Patient-Reported Versus Clinician-Observed Nonulcerative Signs and Symptoms of the Foot in Patients With Diabetes Mellitus. ³⁸	Takehara K...Sanada H	30747799	2019
7	Detection of Trichophyton rubrum and Trichophyton interdigitale in onychomycosis using monoclonal antibodies against Sub6 (Tri r 2). ³⁸	Mehul B...Monod M	30152879	2019
8	Ultrastructural changes of Trichophyton rubrum in tinea unguium after itraconazole therapy in vivo observed using scanning electron microscopy. ³⁸	Yue X...Li Q	30387190	2018
9	Epidemiological and clinical aspects of dermatophytoses in Eastern Slovakia: a retrospective three-year study. ³⁸	Baranova Z...Rimarova K	30817878	2018
10	Molecular Epidemiological Analysis of the Spreading Conditions of Trichophyton in Long-Term Care Facilities in Japan. ³⁸	Suzuki S...Fujitani K	30175735	2018
11	Topical efinaconazole: A promising therapeutic medication for tinea unguium. ³⁸	Noguchi H...Ihn H	30035311	2018
12	Tinea unguium onychomycosis caused by dermatophytes: a ten-year (2005-2014) retrospective study in a tertiary hospital in Singapore. ³⁸	Pang SM...Tan AL	29552686	2018
13	Epidemiology of dermatophytoses in 31 municipalities of the province of Buenos Aires, Argentina: A 6-year study. ³⁸	Mazza M...Mycology Network of the Province of Buenos Aires (MNPBA)	29606407	2018
14	Characterizing the clinical isolates of dermatophytes in Hamadan city, Central west of Iran, using PCR-RLFP method. ³⁸	Farokhipor S...Didehdar M	29439839	2018
15	Subungual Amelanotic Melanoma Masquerading as Onychomycosis. ³⁸	Riahi RR...Goldberg LH	29755903	2018
16	Common Child and Adolescent Cutaneous Infestations and Fungal Infections. ³⁸	Alter SJ...Trevino J	29198783	2018
17	Comment on "Prevalence, Etiology, and Risk Factors of Tinea Pedis and Tinea Unguium in Tunisia". ³⁸	Badri T	29849837	2018
18	Response to: Comment on "Prevalence, Etiology, and Risk Factors of Tinea Pedis and Tinea Unguium in Tunisia". ³⁸	Toukabri N...Sadfi-Zouaoui N	29951161	2018
19	High prevalence of superficial white onychomycosis by Trichophyton interdigitale in a Japanese nursing home with a geriatric hospital. ³⁸	Watanabe S...Mochizuki T	28436564	2017
20	Recurrent dermatophytosis: A rising problem in Sikkim, a Himalayan state of India. ³⁸	Sharma R...Sharma RL	29323069	2017
21	Epidemiology of dermatomycoses in Kerman province, southeast of Iran: A 10-years retrospective study (2004-2014). ³⁸	Salari S...Izadi A	28757272	2017
22	Pathogenic Dermatophytes Survive in Nail Lesions During Oral Terbinafine Treatment for Tinea Unguium. ³⁸	Iwanaga T...Mochizuki T	28281037	2017
23	Examining the accuracy of visual diagnosis of tinea pedis and tinea unguium in aged care facilities. ³⁸	Goto T...Sanada H	28379097	2017
24	Epidemiological status of dermatophytosis in Guilan, north of Iran. ³⁸	Fallahi AA...Rezaei S	29302626	2017
25	New Antifungal Agents and New Formulations Against Dermatophytes. ³⁸	Gupta AK...Versteeg SG	27502503	2017
26	Tinea Unguium: Diagnosis and Treatment in Practice. ³⁸	Asz-Sigall D...Arenas R	27787643	2017
27	Dermatophyte Antigen Kit. ³⁸	Tsunemi Y	28566667	2017
28	[Affinity of Luliconazole for Human Nail Derived Keratin]. ³⁸	Hasuko M...Inagaki K	29187718	2017
29	Prevalence, Etiology, and Risk Factors of Tinea Pedis and Tinea Unguium in Tunisia. ³⁸	Toukabri N...Sadfi-Zouaoui N	28852411	2017
30	Characterization of clinically important dermatophytes in North of Iran using PCR-RFLP on ITS region. ³⁸	Didehdar M...Mondanizadeh M	27496524	2016
31	[Causative agents of superficial mycoses isolated in Dakar, Senegal: Retrospective study from 2011 to 2015]. ³⁸	Diongue K...Ndiaye D	27592054	2016
32	[Tinea unguium with Microsporum langeronii and Trichophyton soudanense revealing tinea capitis with M. langeronii]. ³⁸	Diongue K...Ndiaye D	27592053	2016
33	Clinical study of Dermatophyte Test Strip, an immunochromatographic method, to detect tinea unguium dermatophytes. ³⁸	Tsunemi Y...Hiruma M	26992478	2016
34	Is the Dermatophyte Test Strip truly useful for the diagnosis of tinea unguium? Inquiry into "Clinical study of Dermatophyte Test Strip, an immunochromatographic method, to detect tinea unguium dermatophytes". ³⁸	Watanabe S	27910169	2016
35	Production of an anti-dermatophyte monoclonal antibody and its application: immunochromatographic detection of dermatophytes. ³⁸	Noriki S...Ishida H	27250927	2016
36	Identification of three yeast species using the conventional and internal transcribed spacer region sequencing methods as first or second global record from human superficial infections. ³⁸	Abdel-Sater MA...Soliman Z	27392537	2016
37	Protocol for the systematic review of the prevention, treatment and public health management of impetigo, scabies and fungal skin infections in resource-limited settings. ³⁸	May P...Carapetis J	27659511	2016
38	Epidemiological Aspects of Dermatophytosis in Khuzestan, southwestern Iran, an Update. ³⁸	Rezaei-Matehkolaei A...Sadeghi-Nejad B	26886443	2016
39	Epidemiology of Superficial Fungal Infections in Guangdong, Southern China: A Retrospective Study from 2004 to 2014. ³⁸	Cai W...Yu X	26883512	2016
40	[Superficial mycoses: casuistry of the Mycology Department of the Instituto Nacional de Higiene "Rafael Rangel", Caracas, Venezuela (2001-2014)]. ³⁸	Capote AM...Dolande M	27382801	2016
41	Molecular Characterization and In Vitro Antifungal Susceptibility of 316 Clinical Isolates of Dermatophytes in Iran. ³⁸	Ansari S...Seyedmousavi S	26369643	2016
42	Development and Evaluation of a Novel Real-Time PCR for Pan-Dermatophyte Detection in Nail Specimens. ³⁸	Gong J...Li R	26412381	2016
43	[Affinity of Luliconazole to Keratin Prepared from Healthy Human Nailand Porcine Hoof]. ³⁸	Hasuko M...Tsuboi R	26936352	2016
44	Computational analysis of conserved coil functional residues in the mitochondrial genomic sequences of dermatophytes. ³⁸	Gupta B...Kaur J	28149055	2016
45	Oral Antifungal Drugs in the Treatment of Dermatomycosis. ³⁸	Tsunemi Y	27251319	2016
46	Epidemiology of Dermatophytoses in Crete, Greece. ³⁸	Maraki S...Mavromanolaki VE	27904054	2016
47	A survey of the etiological agents of scalp and nail dermatophytosis in Yazd, Iran in 2014-2015. ³⁸	Sadeghi Tafti H...Zaini F	28680997	2015
48	Dermatophytosis in patients with human immunodeficiency virus infection: clinical aspects and etiologic agents. ³⁸	Costa JE...Coelho MR	26200786	2015
49	Pattern of Dermatophytes in Patients Attend in Mymensingh Medical College Hospital. ³⁸	Monwar S...Sarkar SR	26620004	2015
50	Tinea corporis due to Trichophyton violaceum: A report of two cases. ³⁸	Smriti C...Nitin K	26470976	2015

Sources

Genes for Tinea Unguium

Genes related to Tinea Unguium (1 elite genes):

(show all 19)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	STAT1	Signal Transducer And Activator Of Transcription 1	Protein Coding	400	Pathogenic ⁶
2	GPT	Glutamic--Pyruvic Transaminase	Protein Coding	17.46	GeneCards inferred via : Publications (show sections)
3	SQLE	Squalene Epoxidase	Protein Coding	15.7	DISEASES inferred ¹⁵
4	ARSI	Arylsulfatase Family Member I	Protein Coding	15.63	DISEASES inferred ¹⁵
5	RPS6KB2	Ribosomal Protein S6 Kinase B2	Protein Coding	15.46	DISEASES inferred ¹⁵
6	TMPRSS6	Transmembrane Serine Protease 6	Protein Coding	15.15	DISEASES inferred ¹⁵
7	HLA-B	Major Histocompatibility Complex, Class I, B	Protein Coding	15.11	DISEASES inferred ¹⁵
8	PRDM10	PR/SET Domain 10	Protein Coding	14.4	DISEASES inferred ¹⁵
9	OPRM1	Opioid Receptor Mu 1	Protein Coding	14.1	DISEASES inferred ¹⁵
10	POLB	DNA Polymerase Beta	Protein Coding	13.83	DISEASES inferred ¹⁵
11	CNBP	CCHC-Type Zinc Finger Nucleic Acid Binding Protein	Protein Coding	13.71	DISEASES inferred ¹⁵
12	PPIG	Peptidylprolyl Isomerase G	Protein Coding	13.67	DISEASES inferred ¹⁵
13	HFE	Homeostatic Iron Regulator	Protein Coding	13.66	DISEASES inferred ¹⁵
14	DDX41	DEAD-Box Helicase 41	Protein Coding	13.49	DISEASES inferred ¹⁵
15	TRIR	Telomerase RNA Component Interacting RNase	Protein Coding	5.69	DISEASES inferred ¹⁵
16	SUB1	SUB1 Regulator Of Transcription	Protein Coding	5.66	DISEASES inferred ¹⁵
17	ACOT11	Acyl-CoA Thioesterase 11	Protein Coding	5.28	DISEASES inferred ¹⁵
18	POLR2B	RNA Polymerase II Subunit B	Protein Coding	4.61	DISEASES inferred ¹⁵
19	CBSL	Cystathionine Beta-Synthase Like	Protein Coding	3.92	DISEASES inferred ¹⁵

Sources

Variations for Tinea Unguium

ClinVar genetic disease variations for Tinea Unguium:

⁶

#	Gene	Variation	Type	Significance	SNP ID	GRCh37 Pos	GRCh38 Pos
1	STAT1	NM_007315.3(STAT1): c.821G> A (p.Arg274Gln)	single nucleotide variant	Pathogenic	rs387906760	2:191859910-191859910	2:190995184-190995184

Sources

Expression for Tinea Unguium

Search GEO for disease gene expression data for Tinea Unguium.

Sources

Pathways for Tinea Unguium

Pathways related to Tinea Unguium according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Hfe effect on hepcidin production ¹	9.47	TMPRSS6 HFE

Sources

GO Terms for Tinea Unguium

Cellular components related to Tinea Unguium according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	MHC class I protein complex	GO:0042612	8.62	HLA-B HFE

Biological processes related to Tinea Unguium according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	antigen processing and presentation of peptide antigen via MHC class I	GO:0002474	8.96	HLA-B HFE
2	cellular response to interferon-beta	GO:0035458	8.62	STAT1 DDX41

Sources

Sources for Tinea Unguium

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ TGDB

⁷¹ Tocris

⁷² UMLS

⁷³ UMLS via Orphanet

⁷⁴ UniProtKB/Swiss-Prot

⁷⁵ Wikipedia

Tinea Unguium

Aliases & Classifications for Tinea Unguium

MalaCards integrated aliases for Tinea Unguium:

Classifications:

External Ids:

Summaries for Tinea Unguium

Related Diseases for Tinea Unguium

Diseases related to Tinea Unguium via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Tinea Unguium:

Symptoms & Phenotypes for Tinea Unguium

Symptoms:

MGI Mouse Phenotypes related to Tinea Unguium:

Drugs & Therapeutics for Tinea Unguium

Drugs for Tinea Unguium (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 72 / NDF-RT 51 :

Genetic Tests for Tinea Unguium

Anatomical Context for Tinea Unguium

MalaCards organs/tissues related to Tinea Unguium:

The Foundational Model of Anatomy Ontology organs/tissues related to Tinea Unguium:

Publications for Tinea Unguium

Articles related to Tinea Unguium:

Genes for Tinea Unguium

Genes related to Tinea Unguium (1 elite genes):

Variations for Tinea Unguium

ClinVar genetic disease variations for Tinea Unguium:

Expression for Tinea Unguium

Pathways for Tinea Unguium

Pathways related to Tinea Unguium according to GeneCards Suite gene sharing:

GO Terms for Tinea Unguium

Cellular components related to Tinea Unguium according to GeneCards Suite gene sharing:

Biological processes related to Tinea Unguium according to GeneCards Suite gene sharing:

Sources for Tinea Unguium

Inferred drug relations via UMLS ⁷² / NDF-RT ⁵¹ :